Metabolic bone disease in chronic kidney disease

被引:163
作者
Martin, Kevin J. [1 ]
Gonzalez, Esther A. [1 ]
机构
[1] St Louis Univ, Med Ctr, Div Nephrol, St Louis, MO 63110 USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2007年 / 18卷 / 03期
关键词
D O I
10.1681/ASN.2006070771
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Metabolic bone disease is a common complication of chronic kidney disease (CKD) and is part of a broad spectrum of disorders of mineral metabolism that occur in this clinical setting and result in both skeletal and extraskeletal consequences. Detailed research in that past 4 decades has uncovered many of the mechanisms that are involved in the initiation and maintenance of the disturbances of bone and mineral metabolism and has been translated successfully from "bench to bedside" so that efficient therapeutic strategies now are available to control the complications of disturbed mineral metabolism. Recent emphasis is on the need to begin therapy early in the course of CKD. Central to the assessment of disturbances in bone and mineral metabolism is the ability to make an accurate assessment of the bone disease by noninvasive means. This remains somewhat problematic, and although measurements of parathyroid hormone are essential, recently recognized difficulties with these assays make it difficult to provide precise clinical practice guidelines for the various stages of CKD at the present time. Further research and progress in this area continue to evaluate the appropriate interventions to integrate therapies for both the skeletal and extraskeletal consequences with a view toward improving patient outcomes.
引用
收藏
页码:875 / 885
页数:11
相关论文
共 104 条
[1]   Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism [J].
Akiba, T ;
Marumo, F ;
Owada, A ;
Kurihara, S ;
Inoue, A ;
Chida, Y ;
Ando, R ;
Shinoda, T ;
Ishida, Y ;
Ohashi, Y .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (02) :238-246
[2]  
Almaden Y, 1998, J AM SOC NEPHROL, V9, P1845
[3]  
Almaden Y, 1996, J BONE MINER RES, V11, P970
[4]  
Almadén Y, 2000, J AM SOC NEPHROL, V11, P1712, DOI 10.1681/ASN.V1191712
[5]   HYPERPARATHYROIDISM AND RENAL-FAILURE [J].
ARNAUD, CD .
KIDNEY INTERNATIONAL, 1973, 4 (02) :89-95
[6]   MONOCLONALITY OF PARATHYROID TUMORS IN CHRONIC-RENAL-FAILURE AND IN PRIMARY PARATHYROID HYPERPLASIA [J].
ARNOLD, A ;
BROWN, MF ;
URENA, P ;
GAZ, RD ;
SARFATI, E ;
DRUEKE, TB .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (05) :2047-2053
[7]  
Brandi L, 1998, J INTERN MED, V244, P121
[8]  
BRICKER NS, 1972, NEW ENGL J MED, V286, P1093
[9]   Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: Importance in the interpretation of PTH values [J].
Brossard, JH ;
Cloutier, M ;
Roy, L ;
Lepage, R ;
GasconBarre, N ;
DAmour, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (11) :3923-3929
[10]   1,25-(OH)2D RECEPTORS ARE DECREASED IN PARATHYROID-GLANDS FROM CHRONICALLY UREMIC DOGS [J].
BROWN, AJ ;
DUSSO, A ;
LOPEZHILKER, S ;
LEWISFINCH, J ;
GROOMS, P ;
SLATOPOLSKY, E .
KIDNEY INTERNATIONAL, 1989, 35 (01) :19-23